Your browser doesn't support javascript.
loading
Variation in the Human Leukocyte Antigen system and risk for endemic Burkitt lymphoma in northern Uganda.
Kirimunda, Samuel; Verboom, Murielle; Otim, Isaac; Ssennono, Mark; Legason, Ismail D; Nabalende, Hadijah; Ogwang, Martin D; Kerchan, Patrick; Kinyera, Tobias; Mwebaza, Ivan; Joloba, Moses; Ayers, Leona W; Reynolds, Steven J; Bhatia, Kishor; Onabajo, Olusegun O; Hallensleben, Michael; Biggar, Robert J; Prokunina-Olsson, Ludmila; Goedert, James J; Blasczyk, Rainer; Mbulaiteye, Sam M.
Afiliación
  • Kirimunda S; College of Health Sciences, Makerere University, Kampala, Uganda.
  • Verboom M; Institute of Transfusion Medicine, Hannover, Germany.
  • Otim I; EMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
  • Ssennono M; EMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
  • Legason ID; EMBLEM Study, Kuluva Hospital, Kuluva, Arua & African Field Epidemiology Network, Kampala, Uganda.
  • Nabalende H; EMBLEM Study, Kuluva Hospital, Kuluva, Arua & African Field Epidemiology Network, Kampala, Uganda.
  • Ogwang MD; EMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
  • Kerchan P; EMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
  • Kinyera T; EMBLEM Study, Kuluva Hospital, Kuluva, Arua & African Field Epidemiology Network, Kampala, Uganda.
  • Mwebaza I; EMBLEM Study, St. Mary's Hospital, Lacor, Gulu & African Field Epidemiology Network, Kampala, Uganda.
  • Joloba M; College of Health Sciences, Makerere University, Kampala, Uganda.
  • Ayers LW; College of Health Sciences, Makerere University, Kampala, Uganda.
  • Reynolds SJ; Department of Pathology, The Ohio State University, Columbus, OH, USA.
  • Bhatia K; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Onabajo OO; Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Hallensleben M; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Biggar RJ; Institute of Transfusion Medicine, Hannover, Germany.
  • Prokunina-Olsson L; Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Goedert JJ; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Blasczyk R; Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Mbulaiteye SM; Institute of Transfusion Medicine, Hannover, Germany.
Br J Haematol ; 189(3): 489-499, 2020 05.
Article en En | MEDLINE | ID: mdl-32072624
ABSTRACT
Endemic Burkitt lymphoma (eBL) is an aggressive childhood B-cell lymphoma associated with Plasmodium falciparum (Pf) malaria and Epstein-Barr virus (EBV) infections. Variation in the Human Leukocyte Antigen (HLA) system is suspected to play a role, but assessments using less accurate serology-based HLA typing techniques in small studies yielded conflicting results. We studied 200 eBL cases and 400 controls aged 0-15 years enrolled in northern Uganda and typed by accurate high-resolution HLA sequencing methods. HLA results were analyzed at one- or two-field resolution. Odds ratios and 95% confidence intervals (aOR, 95% CI) for eBL risk associated with common HLA alleles versus alleles that were rare (<1%) or differed by <2% between the cases and controls as the reference category, were estimated using multiple logistic regression adjusting for age, sex, microgeography, region, malaria positivity and treatment history, and genetic variants associated with eBL. Compared to the controls, eBL cases had a lower frequency of HLA-A*02 (aOR = 0·59, 95% CI 0·38-0·91), HLA-B*41 (aOR = 0·36, 95% CI 0·13-1·00), and HLA-B*58 alleles (aOR = 0·59, 95% CI 0·36-0·97). eBL cases had a lower frequency of HLA-DPB1 homozygosity (aOR = 0·57, 95% CI 0·40-0·82) but a higher frequency of HLA-DQA1 homozygosity (aOR = 2·19, 95% CI 1·42-3·37). Our results suggest that variation in HLA may be associated with eBL risk.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma de Burkitt / Antígenos HLA Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Región como asunto: Africa Idioma: En Revista: Br J Haematol Año: 2020 Tipo del documento: Article País de afiliación: Uganda

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfoma de Burkitt / Antígenos HLA Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Región como asunto: Africa Idioma: En Revista: Br J Haematol Año: 2020 Tipo del documento: Article País de afiliación: Uganda